PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34007191-0	2021	Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Sequence Type 11 Due to a Mutation in Plasmid-Borne bla kpc-2 to bla kpc-33, in Henan, China.	avibactam	12-21	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	114-119	
34236545-0	2021	A theoretical approach for the acylation/deacylation mechanisms of avibactam in the reversible inhibition of KPC-2.	avibactam	67-76	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	109-114	
34354959-0	2021	Acquisition of a Stable and Transferable bla NDM-5-Positive Plasmid With Low Fitness Cost Leading to Ceftazidime/Avibactam Resistance in KPC-2-Producing Klebsiella pneumoniae During Treatment.	avibactam	113-122	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	137-142	
34354959-14	2021	Our study described the acquisition of a bla NDM-5-harboring plasmid leading to resistance to ceftazidime/avibactam in KPC-2-producing Klebsiella pneumoniae during treatment.	avibactam	106-115	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	119-124	
35341315-3	2022	To gain insights into ceftazidime-avibactam resistance conferred by D179N/Y variants of KPC-2, crystal structures of these variants were determined.	avibactam	34-43	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	88-93	
35341315-10	2022	Overall, the structural results regarding KPC-2 D179 variants revealed various degrees of destabilization of the Omega loop that contribute to ceftazidime-avibactam resistance, possible substrate-assisted catalysis of ceftazidime, and meropenem and meropenem-vaborbactam susceptibility.	avibactam	155-164	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	42-47	
32719857-0	2020	Phenotypic and genotypic analysis of KPC-51 and KPC-52, two novel KPC-2 variants conferring resistance to ceftazidime/avibactam in the KPC-producing Klebsiella pneumoniae ST11 clone background.	avibactam	118-127	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	66-71	
32729059-0	2021	Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment.	avibactam	25-34	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	86-91	
32729059-1	2021	Three ceftazidime-avibactam-resistant KPC-2-producing Klebsiella pneumoniae strains of ST39 were isolated in Greece, from rectal swabs of three patients after 10-15 days of treatment.	avibactam	18-27	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	38-43	
30753572-0	2019	Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2.	avibactam	12-21	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	85-90	
31551966-0	2019	Ceftazidime/avibactam Improves the Antibacterial Efficacy of Polymyxin B Against Polymyxin B Heteroresistant KPC-2-Producing Klebsiella pneumoniae and Hinders Emergence of Resistant Subpopulation in vitro.	avibactam	12-21	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	109-114	
31740422-8	2020	Genomic characterization showed that a ceftazidime/avibactam-resistant KPC-Kp harboured a mixed population with D179Y mutated KPC-2, while the other two ceftazidime-avibactam-resistant KPC-Kp possessed non-functional ompK35-ompK37 and mutated ompK36 porins associated with higher copy number of blaKPC gene.	avibactam	51-60	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	126-131	
31992391-0	2020	Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019.	avibactam	75-84	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	12-17	
31160285-0	2019	Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2-Bearing Isolates of Klebsiella pneumoniae in a Hollow Fiber Infection Model.	avibactam	37-46	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	55-60	
30753572-1	2019	OBJECTIVES: Ceftazidime/avibactam resistance due to mutation in the omega loop of KPC-2 has been documented in vitro and in vivo.	avibactam	24-33	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	82-87	
30753572-2	2019	This study evaluated the mechanism of ceftazidime/avibactam resistance in a KPC-2-expressing Klebsiella pneumoniae isolated from a patient following ceftazidime/avibactam combination therapy with gentamicin for the treatment of ventilator-associated pneumonia.	avibactam	50-59	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	76-81	
30753572-2	2019	This study evaluated the mechanism of ceftazidime/avibactam resistance in a KPC-2-expressing Klebsiella pneumoniae isolated from a patient following ceftazidime/avibactam combination therapy with gentamicin for the treatment of ventilator-associated pneumonia.	avibactam	161-170	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	76-81	
29021086-0	2017	Genomic characterization of an extensively drug-resistant KPC-2-producing Klebsiella pneumoniae ST855 (CC258) only susceptible to ceftazidime-avibactam isolated in Brazil.	avibactam	142-151	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	58-63	
26169413-10	2015	Median ceftazidime-avibactam MICs were higher against KPC-3 than KPC-2 variants (P = 0.02).	avibactam	19-28	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	65-70